Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 23;13:3467–3476. doi: 10.2147/OTT.S243632

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Li et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Expression of ARL4C in human breast cancer. (A) Expression levels of ARL4C were evaluated using qRT-PCR in breast carcinoma and adjacent normal tissues (n=15). (B) The protein level of ARL4C in breast carcinoma tissues and adjacent normal controls. (C) Hematoxylin and eosin staining, and IHC results for ARL4C. (D) Analysis of ARL4C expression in 1218 breast cancer samples. (E) Kaplan-Meier plots were constructed for 3951 breast cancer patients stratified by the expression of ATF3 (low = 1998, high = 1953). *P < 0.05, **P < 0.01, ***P < 0.001, n ≥ 3.

Abbreviations: GAPHD, glyceraldehydes-3-phosphate dehydrogenase; HE, hematoxylin and eosin; HR, hazard ratio; IHC, immunohistochemical.